Maat Pharma SA (MAAT) — Defensive Interval Ratio
Maat Pharma SA (MAAT) has a Defensive Interval Ratio of 416 days as of June 2025. Defensive assets of €18.26 Million (cash €-, short-term investments €31.00K, receivables €18.23 Million) cover 416 days of daily cash needs of €43.96K/day. Check tangible net worth ratio of Maat Pharma SA to evaluate the tangible quality of the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
Maat Pharma SA Defensive Interval Ratio (2017–2024)
This chart shows how Maat Pharma SA's Defensive Interval Ratio has evolved across 8 annual periods from 2017 to 2024. As of June 2025, the ratio stands at 416 days, meaning defensive assets of €18.26 Million can fund 416 days of operations without new revenue. Also explore MAAT shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Defensive Interval Ratio for Maat Pharma SA (2017–2024)
The table below presents the year-by-year Defensive Interval Ratio for Maat Pharma SA from 2017 to 2024, covering 8 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see market value of Maat Pharma SA.
| Year | DIR (days) | Defensive Assets (EUR) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2024 | 258 days | €10.27 Million | €39.89K/day | €8.69 Million | €66.00K | ▼ -522 days |
| 2023 | 780 days | €24.61 Million | €31.57K/day | €19.41 Million | €34.00K | ▲ +1 days |
| 2022 | 778 days | €19.65 Million | €25.25K/day | €18.54 Million | €63.00K | ▲ +506 days |
| 2021 | 272 days | €3.51 Million | €12.88K/day | €- | €- | ▼ -14 days |
| 2020 | 286 days | €2.24 Million | €7.83K/day | €- | €- | ▲ +78 days |
| 2019 | 208 days | €1.50 Million | €7.21K/day | €- | €- | ▲ +78 days |
| 2018 | 129 days | €794.00K | €6.13K/day | €- | €- | ▲ +128 days |
| 2017 | 1 days | €4.23K | €3.98K/day | €- | €- | — |